ClinicalTrials.gg
RecruitingNCT06094972A-CRA at SiSUpdated Feb 5, 2024

The Effectiveness of A-CRA in Compulsory Institutional Care for Youth

An interventional study of Adolescent Community Reinforcement Approach, A-CRA and TAU in Substance Use Disorders and Criminal Behavior, sponsored by Karolinska Institutet. Recruiting at 4 sites in Sweden. Open to participants aged 16 Years to 21 Years. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
16 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Substance-Related Disorders with a site in Sweden — 2 open to participants now, 4 under way, none of them phase 3. Substance-Related Disorders · Sweden.

Planned enrollment
4th of 20
220 · median 97
Started
2023
with 1 other
No phase
16 of 22
2 open now
Registered
21st of 22
by date
Lead sponsor
8 of 22
Karolinska Institutet

Among the 22 studies in Substance-Related Disorders with a site in Sweden, this one is the 4th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 16 with no phase, and was the 21st registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

2 of the 22 studies in Substance-Related Disorders with a site in Sweden are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 16 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Substance-Related Disorders with a site in Sweden, or all of them as a file.
02

Study summary

Youth with substance use disorder (SUD) and socially disruptive behaviour (such as criminality) who are placed in compulsory institutional care are at high risk of continuing a destructive lifestyle into adulthood. There is a pressing need for effective treatment for this group, yet studies are scarce. The empirically supported SUD treatment Adolescent Community Reinforcement Approach, A-CRA, promotes long-term abstinence, increases social stability and decreases co-morbid psychiatric problems for youth ages 12-25. A-CRA is proven to be one of the most effective SUD treatments for youth but has only been evaluated in outpatient care. Given A-CRA's promising results for youth in vulnerable living situations, it is a reasonable treatment to adjust and evaluate in compulsory care. The main objectives are to evaluate the effectiveness of A-CRA, the short- and long-term effects on social-, emotional- and problem behavior and substance use, for youth placed in compulsory institutional care.

Read the detailed description

Substance abuse and criminality among youth in Sweden are urgent problems. More knowledge on effective interventions is crucial to help vulnerable youth at risk of developing an array of severe problems affecting both themselves, their relatives and society (Grahn, Lundgren Chassler \& Padyab, 2015). Effective help for substance abuse increases chances to abandon criminality and build up a constructive life (Henderson et al, 2016, Chermack et al, 2010). Youth with severe substance abuse and psychosocial problems, such as criminal and socially disruptive behavior, often receive treatment in compulsory institutional care. The responsible party for delivering care in this domain is The Swedish National Board of Institutional Care, (Statens institutionsstyrelse, SiS). SiS provides institutional care on basis of the Swedish laws Care of Young Persons (Special Provisions) Act, LVU, Care of Substance Abusers (Special Provisions) Act, LVM, Secure Youth Care Act, LSU. Treatment is delivered in lockable institutions, situated in different locations around the country. However, the institutional setting differs from standard outpatient care where most substance use treatments have been designed for. For example, the locked ward and security routines pose challenges when fostering pro-social and constructive behavior (Gevers, Poelen, Scholte, Otten \& Koordeman, 2020). Every activity must be thoroughly planned to lower risks of violence or escaping and routines, such as visitations, can lower the ability and motivation to engage in positive activities outside the institution (Brauers, Kroneman, Otten, Lindauer \& Popma, 2016). The Swedish Agency for Health Technology Assessment and Assessment of Social Services, SBU, concluded in a systematic review (2016) that the scientific support for several of the treatment programs conducted at SiS are inadequate. Consequently, that more research on treatment in institutional care is needed, especially high-quality studies with a study design adjusted to the specific conditions prevailing there.

An empirically supported substance use treatment developed for youth ages twelve to twenty five is the Adolescent Community Reinforcement Approach, A-CRA. A-CRA promotes long-term abstinence, increase social stability and decrease depression and other co-morbid psychiatric problems according to a large number of studies since the nineteen seventies (Azrin, Sisson, Meyers, \& Godley, 1982; Dennis et al., 2004; Hunt \& Azrin, 1973; Godley et al., 2014; Godley et al., 2001; Godley, Smith, Passetti, \& Subramaniam, 2014). A-CRA is recommended in national guidelines for the treatment of substance use disorder in adolescents (Socialstyrelsen, 2017). Treatment consists of eighteen procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are happiness scale and treatment goals, functional analysis of substance use behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, communication skills, caregiver sessions, job seeking skills and anger management (Godley, Smith, Myers \& Godley, 2016). Procedures are combined and tailored to youth individual goals and needs (Godley et al., 2016). A-CRA has also proven helpful for justice-involved youth with substance use disorder under probation (Henderson et al. 2016) and for homeless youth (Slesnick et al., 2007). However, as many other psychological treatments, A-CRA has mostly been delivered and evaluated within outpatient care. It is unclear whether A-CRA is as effective when delivered in compulsory care where many adolescents with severe substance use disorder and criminal behavior receive treatment.

The overall objective of this research project is to scientifically evaluate the effectiveness of A-CRA in compulsory institutional care for youth with substance use disorder and criminal behavior. In addition, to explore mechanisms of change, what mediates substance abuse and criminal behavior.

Youth are randomized to either treatment as usual or treatment as usual with the addition of A-CRA. Treatment as usual is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Randomization takes place at site level with even allocation to the groups. Quantitative measurements take place before, during and after treatment as well as follow-up at 1, 3, 6 and 12 months. Primary endpoint is 6 months after treatment completion. Qualitative data will be collected by interviewing participants at 3 month follow-up. Potential adverse events will be collected after treatment completion using open questions and registered when reported by staff in the research group or at KI.

03

Conditions studied

  • Substance Use Disorders
  • Criminal Behavior
04

Who can participate

Ages eligible
16 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 16-21
  • Placed in institutional care
  • Suffers from SUD and socially disruptive behaviour
  • Ability to read and understand and interventions

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive or psychiatric condition preventing the ability to provide or undergo assessment or interventions
  • Serious somatic condition requiring acute medical attention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    TAU + A-CRA

    TAU: Interventions and treatments usually offered and delivered in institutional care. See below for examples. 12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Examples of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to meet youth individual goals and needs.

    Behavioral: Adolescent Community Reinforcement Approach, A-CRA

  • Active comparator
    TAU

    Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.

    Behavioral: TAU

Interventions

  • BehavioralAdolescent Community Reinforcement Approach, A-CRA

    A-CRA consists of eighteen treatment modules/procedures that is delivered in weekly sessions over 12-14 weeks. The overarching goal is to decrease substance use behaviours and other related, problematic behaviours such as acting out when experiencing anger, and to increase prosocial and sober behaviours, relationships and activities. The procedures are: 1) Introduction to A-CRA/treatment agreement, 2) Happiness scale and treatment goals, 3) Homework, 4) Systematic encouragement, 5) Functional analysis of substance use behaviour, 6) Functional analysis of prosocial/sober behaviour, 7) Increasing prosocial activities, 8) Drink/drug refusal, 9) Relapse prevention, 10) Sobriety sampling, 11) Communication skills, 12) Problem-solving, 13) Caregiver sessions, 14) Relationship skills, 15) Couple relationship skills, 16) Job-seeking skills, 17) Anger management, 18) Medication adherence and monitoring. Youths' individual goals and problems guide treatment planning.

  • BehavioralTAU

    Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care in Sweden. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT and PULS, a program for reducing violence and criminal behavior. Also, individually tailored interventions will be included, such as counselling or other psychological interventions. TAU will be thoroughly registered during the study since the sites in the trial differs slightly in what they offer.

06

What researchers measure

Primary outcomes

  1. Social, emotional and behavioural problems

    Measured using the Strengths and Difficulties Questionnaire

    Time frame: 0 weeks, 7 weeks, 14 weeks and at follow-up 1, 3, 6, and 12 months after treatment completion

Secondary outcomes

  1. Self reported substance use

    Self-reported substance use, five questions

    Time frame: 0 weeks, 7 weeks, 14 weeks and at follow-up 1, 3, 6, 12 months after treatment

  2. Use of alcohol

    AUDIT - Alcohol Use Disorders Identification Test (Saunders et al, 1993)

    Time frame: 0 weeks, 14 weeks and at follow-up 1, 6 and 12 months after treatment completio

  3. Use of illegal drugs

    Drug Use Disorders Identification Test (DUDIT; Berman, Bergman, Palmstierna, \& Schlyter, 2005)

    Time frame: 0 weeks, 14 weeks and at follow-up 1, 6 and 12 months after treatment completion

  4. Number of days until the first relapse

    Self-reported substance use, five questions

    Time frame: 0 weeks, 7 weeks, 14 weeks and at follow-up 1, 3, 6 and 12 months after treatment completion

  5. Aggressive behavior

    Measured using the Bröset Violent Checklist (Koskela, 2012)

    Time frame: 0 weeks, 7 weeks and 14 weeks and at follow-up 1 month after treatment completion

  6. Goal directed behavior and values

    Bull's-Eye Values Survey (BEVS; Lundgren et al., 2012)

    Time frame: 0 weeks, 7 weeks, 14 weeks and at follow-up 1, 3, 6, 12 months after treatment

  7. Psychological flexibility

    Avoidance and Fusion Questionnaire Short Version (AFQ-Y8; Livheim et al.,2016)

    Time frame: 0 weeks, 7 weeks, 14 weeks and at follow-up 1, 3, 6, 12 months after treatment

07

Study locations

4 of 4 sites recruiting
  • Sundbo
    Fagersta, Västmanland, Sweden
    Recruiting
  • Fagersta
    Lindome, Västra Götaland, Sweden
    Recruiting
    • Kristina Schultz · Contact
  • Statens institutionsstyrelse, SiS, Johannisberg
    Kalix, Sweden
    Recruiting
    • Stefan Granström · Contact
  • Statens institutionsstyrelse, SiS, Ljungbacken
    Uddevalla, Sweden
    Recruiting
    • Lisa Lidström, Msc · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2025, 24 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 23, 2023
StartActual
Sep 15, 2023
Primary completionEst.
Sep 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06094972
Responsible party
Tobias Lundgren (PhD, Associate Professor, Karolinska Institutet) — Principal investigator
First posted
Oct 23, 2023
Start date
Sep 15, 2023
Primary completion
Sep 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 5, 2024

Study contacts

Tobias Lundgren, PhD
Contact
tobias.lundgren@ki.se
070-612 45 55
Sven Alfonsson, PhD
Contact
sven.alfonsson@ki.se
0730415125
Tobias Lundgren, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion